title: C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register.
abstract: OBJECTIVE
  To study the prognosis of patients with newly diagnosed Type 2 diabetes in primary care in relation to their baseline C-peptide concentration.
  
  
  METHODS
  C-peptide concentrations were determined in 399 patients aged < 65 years with newly diagnosed Type 2 diabetes using the Skaraborg Diabetes Register, Sweden. Data on cardiovascular complications and death were extracted from national registers and a local study of retinopathy. Statistical analyses were performed using Cox regression.
  
  
  RESULTS
  An analysis of C-peptide concentrations in quartiles, after adjusting for confounders, showed that patients in the highest quartile had a 2.75-fold higher risk of death from all causes compared with those in the lowest quartile (CI 1.17-6.47). By contrast, C-peptide concentration was not associated with the incidence of cardiovascular events or the development of retinopathy.
  
  
  CONCLUSIONS
  Measurement of C-peptide concentration at diagnosis could help identify patients who are at high risk and who presumably would benefit from more intensive treatment.
authors.affiliation: Husensjö Health Care Centre, Helsingborg, Sweden; Centre for Primary Health Care Research, Department of Clinical Sciences in Malmö, Lund University, Skövde, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Pikkemaat
authors.forename: O
authors.initials: O
authors.lastname: Melander
authors.forename: S
authors.initials: S
authors.lastname: Mölstad
authors.forename: G
authors.initials: G
authors.lastname: Garberg
authors.forename: K B
authors.initials: KB
authors.lastname: Boström
mesh_terms: D000375:Aging / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000401:mortality / Q000517:prevention & control; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications / Q000401:mortality*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000401:mortality*; D003930:Diabetic Retinopathy / Q000097:blood* / Q000401:mortality / Q000517:prevention & control; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011379:Prognosis; D016016:Proportional Hazards Models; D012042:Registries; D012307:Risk Factors; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002096:C-Peptide